ASND (Ascendis Pharma AS) Pre-Tax Income: $111 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASND Ascendis Pharma AS ASND
41 GF Score
Price $268.02
! 3 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Pre-Tax Income?

Ascendis Pharma AS ASND -0.94% 41 Pre-Tax Income is $111 Mil as of Jun. 2026. GuruFocus rates ASND with a GF Score™ of 41/100. The stock has 3 warning signs investors should review.

Pretax income is the income that a company earns before paying income taxes. Ascendis Pharma AS's pretax income for the three months ended in Jun. 2026 was $265 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $111 Mil. Ascendis Pharma AS's pretax margin was 67.82%.

During the past 13 years, Ascendis Pharma AS's highest Pretax Margin was 9.11%. The lowest was -8127.44%. And the median was -1362.67%.


Ascendis Pharma AS  (NAS:ASND) Pre-Tax Income Explanation

Ascendis Pharma AS's Pretax Margin for the quarter that ended in Jun. 2026 is calculated as

Pretax Margin=Pretax Income/Revenue
=265.084/390.881
=67.82%

During the past 13 years, Ascendis Pharma AS's highest Pretax Margin was 9.11%. The lowest was -8127.44%. And the median was -1362.67%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma AS Pre-Tax Income Related Terms


Ascendis Pharma AS Pre-Tax Income Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Pre-Tax Income Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -433.84 -612.09 -517.06 -390.83 -249.01

Ascendis Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.38 -67.34 -31.27 -55.70 265.08

ASND vs JAZZ, BBIO, EXEL: Pre-Tax Income Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Pre-Tax Income vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Pre-Tax Income falls into.


ASND
41GF Score
Ascendis Pharma AS ASND
Pre-Tax Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Ascendis Pharma AS's Pretax Income for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-159.568+-36.889+-94.434+17.917+23.968
=-249

Ascendis Pharma AS's Pretax Income for the quarter that ended in Jun. 2026 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=253.992+12.28+-16.328+5.563+9.577
=265

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $111 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pre-Tax Income →
What does a Pre-Tax Income of $111 Mil mean?
Ascendis Pharma AS (ASND) has a Pre-Tax Income of $111 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Pre-Tax Income too high?
Ascendis Pharma AS's current Pre-Tax Income is $111 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Pre-Tax Income compare to JAZZ and BBIO?
Ascendis Pharma AS's Pre-Tax Income of $111 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Pre-Tax Income is $111 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Pre-Tax Income of $111 Mil. The current Pre-Tax Income is $111 Mil. Ascendis Pharma AS's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Pre-Tax Income is $111 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
41GF Score

Get the complete analysis for ASND

Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$268.02
Price